KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Restructuring Costs (2022 - 2025)

Pacira BioSciences has reported Restructuring Costs over the past 4 years, most recently at $851000.0 for Q4 2025.

  • For Q4 2025, Restructuring Costs fell 82.38% year-over-year to $851000.0; the TTM value through Dec 2025 reached $14.5 million, up 87.78%, while the annual FY2025 figure was $14.1 million, 83.23% up from the prior year.
  • Restructuring Costs for Q4 2025 was $851000.0 at Pacira BioSciences, down from $6.8 million in the prior quarter.
  • Over five years, Restructuring Costs peaked at $10.9 million in Q4 2022 and troughed at -$1.8 million in Q3 2024.
  • A 4-year average of $2.7 million and a median of $1.4 million in 2023 define the central range for Restructuring Costs.
  • Biggest five-year swings in Restructuring Costs: crashed 983.0% in 2024 and later skyrocketed 484.54% in 2025.
  • Year by year, Restructuring Costs stood at $10.9 million in 2022, then plummeted by 113.32% to -$1.5 million in 2023, then soared by 432.64% to $4.8 million in 2024, then plummeted by 82.38% to $851000.0 in 2025.
  • Business Quant data shows Restructuring Costs for PCRX at $851000.0 in Q4 2025, $6.8 million in Q3 2025, and $634000.0 in Q2 2025.